MedTrace Logo

A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care

NCT07742527 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2026-08-03

No results posted yet for this study

Summary

This study aims to compare how belantamab behaves in the body when given as an injection under the skin (SC) versus into a vein (IV) in participants with multiple myeloma who are receiving standard of care treatment, to enable eventual development of SC formulation. It will assess how much belantamab is absorbed and how long it stays in the blood as well as assess whether it is safe and tolerated well by participants.

Conditions

Interventions

DRUG

Recombinant Human Hyaluronidase PH20 (rHuPH20)

rHuPH20 will be administered via SC route.

DRUG

Standard of care

Participants will receive standard of care: Lenalidomide and/or anti-CD38 mAb as maintenance therapy.

DRUG

Belantamab SC

Belantamab will be administered via SC route.

DRUG

Belantamab IV

Belantamab will be administered via IV route.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-16
Primary Completion
2027-08-05
Completion
2030-03-18
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07742527 on ClinicalTrials.gov